LPS 48 hour

Contact


Ms Lydia Noa
+44 (0)20 7594 2151
lydia.noa@imperial.ac.uk

Lead academic
Professor Clare Lloyd

If you are interested in working with a particular group, please e-mail anyone of the Principal Investigators through the e-mail links on individual webpages.

Study with NHLI

What we do

The Inflammation Repair and Development (IRD) Section encompasses research in immunobiology of leukocytes, the blood cells that function as part of the body's immune system, integrated with investigation of developmental, environmental or medical factors that contribute to lung disease. We study diseases including asthma, chronic obstructive pulmonary disorder (COPD), cystic fibrosis, interstitial lung disease (ILD), respiratory infections and acute respiratory distress syndrome (ARDS). 

Why it is important

  1. Respiratory disease is a significant cause of mortality and morbidity worldwide, however effective treatments for many respiratory diseases are limited. At the same time certain medical interventions aimed at prolonging life, such as mechanical ventilation, can cause injury to the lungs which may lead to acute lung damage or long-term structural changes. Our section aims to identify new treatments to repair damaged lungs.
  2. A fundamental knowledge of the immunobiology of leukocytes is essential to understand how the body reacts to infection and injury. We investigate leukocyte development, from bone marrow, their recruitment, retention and recirculation through tissues and their role in maintenance of immune homeostasis within the lung as well as their contribution to host defence during infections.  

Impact of our research

Research by groups in our section has led to:

  1. A new sub-lingual (under the tongue) treatment for hayfever.
  2. Identified a novel class of drugs to reduce inflammation in chronic neutrophilic lung diseases such as COPD and severe asthma that are currently being developed for use in man.
  3. Pioneered tailored treatments for children with asthma by using age-appropriate in vivo models along with patient samples.
  4. Identified key proteins that are altered in in patients with idiopathic pulmonary fibrosis (IPF), these are currently being followed up in international clinical trials as potential treatment biomarkers.

Summary of current research

Our section's research encompasses two main areas: 

extra information

Events & meetings

  • Through the monthly IRD seminar series leading experts in the fields of inflammation, repair and development from around the UK and beyond present their work to the department. They also spend the day in the department, meeting the students, postdocs and Principal Investigators. 

Find out more about IRD Monday Seminar Series and Journal Club.

 

Key techniques

Key publications

Assessment of corticosteroid response in paediatric patients with severe asthma by using a multidomain approach. Bossley CJ, Fleming L, Ullmann N, Gupta A, Adams A, Nagakumar P, Bush A, Saglani S. J Allergy Clin Immunol. 2016 Aug;138(2):413-420.e6. doi: 10.1016/j.jaci.2015.12.1347.

Deficient retinoid-driven angiogenesis may contribute to failure of adult human lung regeneration in emphysema. Ng-Blichfeldt JP, Alçada J, Montero MA, Dean CH, Griesenbach U, Griffiths MJ, Hind M. Thorax. 2017 Jan 13. pii: thoraxjnl-2016-208846. doi: 10.1136/thoraxjnl-2016-208846.

Pulmonary epithelial derived TGF-β1 is a critical cofactor for enhanced innate lymphoid cell functionL Denney, AJ Byrne, TJ Shea, J S Buckley, JE Pease, GM. F. Herledan SA. Walker, LG. Gregory, CM Lloyd. 2015. Immunity. 43:945-58. PMID: 26588780. 

A critical role for IRF5 in regulating allergic airway inflammation. Byrne AJ, Weiss M, Mathie SA, Walker SA, Eames HL, Saliba D, Lloyd CM, Udalova IA. Mucosal Immunology, 2016 Oct.

Matrikines are key regulators in modulating the amplitude of lung inflammation in acute pulmonary infectionS. Akthar, D. Patel, R. Beale, T. Peiró, X. Xu, A. Gaggar, P.L. Jackson,  J. E. Blalock, C.M. Lloyd, and R.J. Snelgrove. Nature Communications 2015 Sep 24;6:8423.

Distinct conformations of the chemokine receptor CCR4 with implications for its targeting in allergy. Viney JM, Andrew DP, Phillips RM, Meiser A, Patel P, Lennartz-Walker M, Cousins DJ, Barton NP, Hall DA, Pease JE. J Immunol. 2014 Apr 1;192(7):3419-27. doi: 10.4049/jimmunol.1300232.

Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicenter PROFILE studyJenkins RG, Simpson JK, Saini G, Bentley JH, Russell AM, Braybrooke R, Molyneaux PL, McKeever TM, Wells AU, Flynn A, Hubbard RB, Leeming DJ, Marshall RP, Karsdal MA, Lukey PT, Maher TM. Lancet Respir Med. 2015 Jun;3(6):462-72.

Public Engagement

As a section we are actively involved in public engagement activities for the department and Professor Sara Rankin is NHLI's Divisional Lead for Outreach.

We have recently received funding from the Wellcome Trust for a new project called Breathing Together - details will follow once the project launches in 2017.

Previous projects include:

For full details of all of NHLI's public engagement activities see our webpages.

Our researchers